Table 2. The target sites of Bcr-Abl tyrosine kinase inhibitors and cardiotoxicity in patients with chronic myelogenous leukemia.
| Kinase/TKI | Imatinib | Nilotinib | Dasatinib | Bostinib | Ponatinb |
|---|---|---|---|---|---|
| Bcr-Abl | + | ++ | ++ | ++ | |
| Bcr-Abl (T315I) | ++ | ||||
| VEGFR | ++ | ++ | |||
| FGFR | ++ | ++ | |||
| PDGFR | + | + | ++ | ++ | |
| SRC | ++ | ++ | + | ||
| DDR1 | + | + | ++ | ||
| Tie2 | ++ | ||||
| cKIT | + | + | ++ | ++ |
| Cardiotoxicity/TKI | Imatinib | Nilotinib | Dasatinib | Bostinib | Ponatinb |
|---|---|---|---|---|---|
| PAOD | ++ | +/− | ++ | ||
| IHD/CVA | + | + | |||
| VTE | + | ||||
| Pulmonary hypertension | + | ||||
| Platelet dysfunction | + | + | |||
| Hypertension | + | ++ | |||
| Hyperglycemia | a | + | |||
| Dyslipidemia | a | + |
Bcr-Abl tyrosine kinase inhibitors used to treat chronic myelogenous leukemia have multiple target sites, and each drug is associated with different cardiovascular adverse reactions.
a: Imatinib has been shown to have positive effects on glucose blood levels, as well as lipid profile.
Abbreviations: CVA: cerebrovascular accident, DDR1: discoidin domain receptor 1, HT: hypertension, IHD: ischemic heart disease, PAOD peripheral arterial occlusive disease, PDGFR: platelet-derived growth factor receptor, TKI: Tyrosine kinase inhibitors, EGFR: vascular endothelial growth factor receptor, VTE: venous thromboembolism.
Quoted from the following articles:
(28) Moslehi JJ, Deininger M. J Clin Oncol 2015; 33: 4210–4218.
(29) Pasvolsky O et al., Cardio-Oncology 2015; 1: 5–15.